Takeda Pharmaceutical (TAK) reports $16.37M in 13F holdings, 9 positions

Rhea-AI Filing Summary

Takeda Pharmaceutical Co Ltd filed a Form 13F reporting institutional holdings through its reporting manager. The filing lists 9 holdings with a total reported market value of $16,369,175 and names one other included manager, Takeda Vaccines, Inc. The signature is dated 11-13-2025.

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F COVER PAGE

OMB APPROVAL

OMB Number:			3235-0006
Estimated average burden
hours per response:			23.8

Report for the Calendar Year or Quarter Ended: 09-30-2025

Check here if Amendment		Amendment Number:
This Amendment (Check only one.):		is a restatement.
		adds new holdings entries.

Institutional Investment Manager Filing this Report:
Name:	TAKEDA PHARMACEUTICAL CO LTD
Address:	1-1, Nihonbashi-Honcho 2-Chome, Chuo-Ku
	Tokyo, M0 103-8668
Form 13F File Number:	028-24938
CRD Number (if applicable):
SEC File Number (if applicable):

The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form.

Person Signing this Report on Behalf of Reporting Manager:
Name:		Max Heuer
Title:		Authorized Signatory
Phone:		857-757-6000
Signature, Place, and Date of Signing:
/s/ Max Heuer			Cambridge, MA	11-13-2025
[Signature]			[City, State]	[Date]

Report Type (Check only one.):
X	13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.)
	13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).)
	13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).)

Form 13F Summary Page
	Report Summary:
	Number of Other Included Managers:		1
	Form 13F Information Table Entry Total:		9
	Form 13F Information Table Value Total:		16,369,175
			(round to nearest dollar)

List of Other Included Managers:
Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report.
[If there are no entries in this list, state "NONE" and omit the column headings and list entries.]
	No.	Name	Form 13F File No.	CRD No. (if applicable)	SEC File No. (if applicable)	CIK
	1	Takeda Vaccines, Inc.	028-24939

FAQ

What does Takeda's Form 13F (TAK) disclose?

It discloses institutional holdings totaling $16,369,175 across nine positions. The filing lists the reporting manager and one included manager, Takeda Vaccines, Inc., and is signed on 11-13-2025, indicating the holdings reported by the manager at that reporting date.

How many holdings and what total value are reported by TAK?

Nine holdings are reported with a total value of $16,369,175. The Form 13F Information Table Entry Total is nine, and the Form 13F Information Table Value Total is shown as $16,369,175 in the filing summary.

Who filed the Form 13F for Takeda (TAK)?

Takeda Pharmaceutical Co Ltd's institutional investment manager filed the report. The report is signed by Max Heuer as Authorized Signatory, and it lists an additional included manager, Takeda Vaccines, Inc., with its Form 13F file number shown.

Does the Form 13F indicate any amendments or restatements?

The cover page shows standard amendment checkboxes but does not state a restatement here. The summary indicates this is a Form 13F Holdings Report reporting all holdings of this reporting manager; amendment specifics are not detailed in the provided excerpt.